Medtronic's SYMPLICITY HTN-3 trial fails to meet primary efficacy endpoint Medtronic announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board concluded that there were no safety concerns in the study. Based on these clinical trial findings, Medtronic intends to formulate a panel of independent advisors made up of physicians and researchers who will be asked to make recommendations about the future of the global hypertension clinical trial program, as well as provide advice on continued physician and patient access to the Symplicity technology in countries with regulatory approvals.
News For MDT From The Last 14 Days
Check below for free stories on MDT the last two weeks.